Bangladesh passed an approval on Thursday for obtaining 30 million doses of India’s Covid-19 vaccine candidate Covishield, which has been co-developed by AstraZeneca and Oxford University.
Bangladesh’s drug regulator, Directorate General of Drug Administration (DGDA) has given authorization to Beximco Pharmaceuticals Limited regarding the import and distribution of the Covid-19 vaccine from India. For the firsts six months pertaining to the first phase, Beximco will obtain five million vaccine doses on monthly basis, as reported by Dhaka Tribune.
DGDA Deputy Director Md Salauddin stated, “Beximco pharma can now import and distribute the COVID-19 vaccine from India. It will first supply the vaccine in meeting the government’s requirements. Then it can supply the vaccine to private hospitals approved by the government.”
On Monday this week, the government had directed a no-objection certificate (NOC) for the emergency use of the Covid-19 vaccine developed by Oxford-AstraZeneca collaboration. Post the authorization of UK for the vaccine, Indian regular passed the approval for the emergency use of the vaccine, as stated by Dhaka Tribune. India’s Serum Institute of India (SII) is the local manufacturing company for the Covid-19 vaccine developed by Oxford University-AstraZeneca. Bangladesh had signed an agreement with the SII with which Beximco Pharma will be acquiring 30 million doses of the vaccine. Further, the DGDA had granted an approval on Wednesday for commencing the clinical trials Globe Biotech Limited’s manufacture of its Covid-9 vaccine, Bongavax, according to the reports of Dhaka Tribune.
- Statewide Transport Workers’ Strike from Dec 31: Disruption in Bus Services Likely
- Mandya Kannada Sahitya Sammelana: Traffic Diversion on Bengaluru-Mysuru Expressway
- Ravichandran Ashwin Announces Sudden Retirement from International Cricket
- Free Cancer Vaccine Distribution in Russia from 2025: A Remarkable Medical Breakthrough
- Train Services Delayed Between Bengaluru-Mysuru: Introduction of New Train Numbers
